lycopene

AssetAlso LaFlavon, E-160D, FEMA NO. 4110, INS-160D

Antioxidant carotenoid supplement

Stage: Phase 3
Modality: Supplement
Target: Oxidative stress and ROS signalling; 1
Indication: 22
Trials: 1
Developer

Indications

1

Metabolic disease
Phase 3, Unknown, NCT01286909, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials22
Evidence for its targets2
Signals11

Every asset’s record: target, stage, trials and the evidence behind it.